Drug Profile
NP 001
Alternative Names: NP 001 - Neuvivo; NP-001Latest Information Update: 03 Apr 2023
Price :
$50
*
At a glance
- Originator
- Developer Neuraltus Pharmaceuticals; Neuvivo
- Class Antidementias; Antiparkinsonians; Neuropsychotherapeutics; Small molecules; Vascular disorder therapies
- Mechanism of Action Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
- Phase I Alzheimer's disease; Frontotemporal dementia; Huntington's disease; Immunological disorders; Multiple sclerosis; Muscular dystrophies; Parkinson's disease; Vascular dementia
- Discontinued Ataxia telangiectasia
Most Recent Events
- 30 Mar 2023 Pharmacodynamics data from a phase II trial in Amyotrophic lateral sclerosis released by Neuvivo
- 20 Sep 2022 Phase-I clinical trials in Frontotemporal dementia in USA (unspecified route) prior to September 2022 (Neuvivo pipeline, September 2022)
- 20 Sep 2022 Phase-I clinical trials in Huntington's disease in USA (unspecified route) prior to September 2022 (Neuvivo pipeline, September 2022)